ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Pfizer's Coming for AbbVie's Market Share. ... (now that Humira is seeing competition from generics as a result of going over the patent cliff in the U.S. this year).

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

The stock's rise snapped a three-day losing streak.

AbbVie’s $2.1 billion acquisition of Capstan Therapeutics aims to advance in vivo CAR-T therapies, transforming autoimmune disease treatment by resetting the immune system.

Pfizer's net income was $7,864 million in Q2 2022, up 131.8% QoQ. AbbVie's net income was $924 million in Q2 2022, up 20.6% year-on-year. It is unlikely that the Inflation Reduction Act will have ...

This was the stock's third consecutive day of losses.

Lawmakers in Congress busily marking up bills on pharmacy middlemen this week might want to pay heed to AbbVie’sABBV-0.77%decrease; red down pointing triangle latest earnings results. Investors ...

Revenue at North Chicago-based AbbVie dove by nearly 10% during the first few months of this year — a drop that comes as its bestselling drug Humira faces competition for the first time in the U ...